Lerkanydypyn – Zanidip-Recordati tablets coated. 20 mg 56 pcs

Description

Latin name

ZANIDIP-RECORDATI

Packing

56 pieces

¤ °Ñ ¼ ° º ¾ » ¾ ³ ¸Ñ‡ с º ¾ ´ ¹ÑÑ ² ¸

— ° ½ ¸ ´ ¸ ¿-   º ¾Ñ ´ °Ñ ¸ – ± » ¾ º °Ñ ¾Ñ « ¼ ´ » ½ ½ х » º ° »ÑŒÑ† ¸ ² х º ° ½ ° » ¾ ². › Ñ º ° ½ ¸ ´ ¸ ¿ ¸ ½ я ² »Ñ Ñ ÑÑ Ñ °Ñ† ¼ ¸Ñ‡ с º ¾ ¹ с ¼ сью ¿Ñ ° ² ¾- (R) ¸ » ² ¾ ²Ñ °Ñ‰ °ÑŽÑ‰ ¸Ñ…ся (S) ÑÑ Ñ ¾ ¸ · ¾ ¼ Ñ ¾ ², ¿Ñ ¾ ¸ · ² ¾ ´ ½ ¾ 1,4- ´ ¸ ³ ¸ ´Ñ ¾ ¿ ¸Ñ ¸ ´ ¸ ½ °, с ¿ ¾Ñ ¾ ± ½ ¸ · ± ¸Ñ °Ñ »ÑŒ ½ ¾ ± » ¾ º ¸Ñ ¾ ² °Ñ ь Ñ ¾ º ¸ ¾ ½ ¾ ² º ° »ÑŒÑ† ¸Ñ ² ½ÑƒÑ Ñ ÑŒ º » Ñ ¾ º с ¾ÑÑƒ ´ ¸ÑÑ ¾ ¹ ÑÑ ½ º ¸,с Ñ ´ ч ½ º » Ñ º ¸ ¸ º » Ñ º ¸ ³ » ° ´ º ¾ ¹ ¼ÑƒÑ ºÑƒ » °Ñ ÑƒÑ . œ х ° ½ ¸ · ¼ ³ ¸ ¿ ¾Ñ ½ · ¸ ² ½ ¾ ³ ¾ ´ ¹ÑÑ ² ¸Ñ ¾ ±ÑƒÑ » ¾ ² » ½ ¿Ñ я ¼ ¼ Ñ » ° ºÑ ¸Ñ ующ ¸ ¼ ´ ¹ÑÑ ² ¸ ¼ ½ ° ³ » ° ´ º ¾ ¼ ш ч ½ º » Ñ º ¸ с ¾ÑÑƒ ´ ¾ ². ž ± » ° ´ ° Ñ ¿Ñ ¾ » ¾ ½ ³ ¸Ñ ¾ ² ° ½ ½ ¼ ° ½Ñ ¸ ³ ¸ ¿ Ñ Ñ ½ · ¸ ² ½ ¼ ´ ¹ÑÑ ² ¸ ¼. ¢ Ñ ° ¿ ²Ñ ¸Ñ‡ с º ¸ ¹ эфф ºÑ ´ ¾ÑÑ ¸ ³ ° Ñ ÑÑ ч Ñ · 5-7 ч °Ñ ¾ ² ¿ ¾Ñ » ¿Ñ ¸ ¼ ° ² ½ÑƒÑ Ñ ÑŒ ¸ ´ » ¸Ñ »ÑŒ ½ ¾ÑÑ ь ³ ¾ с ¾Ñ…Ñ ° ½Ñ Ñ ÑÑ ² Ñ Ñ‡ ½ ¸ ÑÑƒÑ ¾ º (24 ч °Ñ ¾ ²). ‘ » ° ³ ¾ ´ °Ñ я ² с ¾ º ¾ ¹ с » ºÑ ¸ ² ½ ¾ÑÑ ¸ º ³ » ° ´ º ¾ ¼ ш ч ½ ¼ º » Ñ º ° ¼ с ¾ÑÑƒ ´ ¾ ² ¾Ñ Ñ ¸Ñ† °Ñ »ÑŒ ½ ¾ ¸ ½ ¾Ñ Ñ ¾ ¿ ½ ¾ ´ ¹ÑÑ ² ¸ ¾Ñ ÑÑƒÑ ÑÑ ²Ñƒ Ñ . › Ñ º ° ½ ¸ ´ ¸ ¿ ¸ ½ я ² »Ñ Ñ ÑÑ ¼ Ñ ° ± ¾ » ¸Ñ‡ с º ¸ ½ ¹Ñ Ñ ° »ÑŒ ½ ¼ ¿Ñ ¿ °Ñ °Ñ ¾ ¼ ¸ ½ ¾ º ° · ² ° Ñ ÑÑƒÑ‰ ÑÑ ² ½ ½ ¾ ³ ¾ ² ¾ · ´ ¹ÑÑ ² ¸Ñ ½ ° с ¾ ´ Ñ ¶ ° ½ ¸ » ¸ ¿ ¾ ¿Ñ ¾Ñ ¸ ½ ¾ ² ¸ ° ¿ ¾ » ¸ ¿ ¾ ¿Ñ ¾Ñ ¸ ½ ¾ ² ² с ² ¾Ñ ¾Ñ º ºÑ ¾ ² ¸, ° Ñ ° º ¶ ½ ¸ · ¼ ½Ñ Ñ » ¸ ¿ ¸ ´ ½ ¹ ¿Ñ ¾Ñ„ ¸ »ÑŒ у ¿ °Ñ† ¸ ½Ñ ¾ ² с °Ñ Ñ Ñ ¸ ° »ÑŒ ½ ¾ ¹ ³ ¸ ¿ Ñ Ñ ½ · ¸ ¹.

Indications

Essential mild to moderate hypertension.

Contraindications

Hypersensitivity,

decompensated heart failure, unstable angina, aortic stenosis, recent myocardial infarction (within 1 month),

severe impaired liver function, impaired renal function (CK less than 12 ml / min, s, children) not using reliable contraception, pregnancy, lactation,

childhood and adolescence (up to 18 years).

For LF containing lactose (optional): lactose intolerance, galactosemia, glucose / galactose malabsorption syndrome.

Caution. Renal and / or liver failure, CVD (without pacemaker), coronary heart disease, LV dysfunction, advanced age.

Special instructions

During treatment, care must be taken when driving vehicles and engaging in potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.

Composition

One film-coated tablet contains:

active ingredient: lercanidipine hydrochloride 20 mg

excipients: lactose monohydrate – 60 mg, microcrystalline cellulose – 78 mg, sodium carboxymethyl starch – 31 mg, povidone K30 – 9 mg, magnesium stearate – 2 mg.

sheath composition: opadray pink (02F25077) – 6 mg (hypromellose, talc, titanium dioxide (E171), macrogol 6000, red dye iron oxide (E172)).

Dosage and administration of

Zanidip-Recordati taken orally, in the morning, at least 15 minutes before meals, without chewing, washed down with a sufficient amount of water, 10 mg once a day.

Dose may be increased to 20 mg (depending on individual effect). Increasing the dose to 20 mg is carried out 2 weeks after the start of the drug.

In case of mild or moderate renal or hepatic insufficiency, increase the dose to 20 mg per day with caution.

Side effects

From the nervous system: rarely – drowsiness infrequently – headache, dizziness

from the immune system: very rarely – increased sensitivity

from the cardiovascular system: not often – tachycardia, palpitations “flushing” of blood to the skin of the face rarely – angina very rarely – fainting, pronounced decrease in blood pressure, chest pain, myocardial infarction

From the digestive system: rarely – nausea, vomiting, diarrhea, abdominal pain, dyspepsia, very rarely – increased activity of “liver” enzymes (reversible)

From skin: rarely – skin rash

From the musculoskeletal system: rarely – myalgia

From the urinary system: rarely – polyuria

General disorders and local reactions: not often – peripheral edema, rarely – asthenia, fatigue is very rare – gingival hyperplasia.

overdose

Symptoms: peripheral vasodilation with marked decrease in BP and reflex tachycardia, increase in frequency and duration of angina attacks, myocardial infarction.

Treatment: symptomatic therapy.

Storage Conditions

At a temperature not exceeding 30 ° C. Keep out of reach of children.

PMA pills

Recordati chemical kai and the pharmaceutical industry, Italy